Sign Out
Urofollitropin (Endogen HP) is contraindicated in women who have: A high FSH level indicating primary ovarian failure: Uncontrolled thyroid and adrenal dysfunction.
An organic intracranial lesion such as pituitary tumor.
The presence of any cause on infertility other than anovulation.
Abnormal bleeding of undetermined origin.
Ovarian cysts or enlargement not due to polycystic ovary syndrome.
Prior hypersensitivity to urofollitropins, purified.
Urofollitropin (Endogen HP) is contraindicated in women who are pregnant and may cause fetal harm when administered to a pregnant women. There are limited human data on the effects of Urofollitropin (Endogen HP) when administered during pregnancy.
Continue with Google